Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data from a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes

American Journal of Kidney Diseases

Volumn 66, Issue 3, 2015, Pages 441-449

  Cooper, Mark E ^a   Perkovic, Vlado ^b   McGill, Janet B ^c   Groop, Per Henrik ^a,d,e   Wanner, Christoph ^f   Rosenstock, Julio ^g   Hehnke, Uwe ^h   Woerle, Hans Juergen ^h   Von Eynatten, Maximilian ^h  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c WASHINGTON UNIVERSITY   (United States)

^d BIOMEDICUM HELSINKI   (Finland)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f UNIVERSITY OF WÜRZBURG   (Germany)

^g DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^h BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

albuminuria; glucose control; glucose lowering therapy; hyperglycemia; Index Words Dipeptidyl peptidase 4 (DPP 4) inhibition; kidney disease end points; linagliptin; pooled analysis; renal function; renal risk; type 2 diabetes mellitus (T2DM)

Indexed keywords

HEMOGLOBIN A1C; INSULIN; LINAGLIPTIN; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; PURINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ACUTE KIDNEY FAILURE; ADULT; AGED; ALBUMINURIA; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; META ANALYSIS; MIDDLE AGED; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

AGED; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PURINES; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84939565970     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2015.03.024     Document Type: Article

References (37)

1. R.M. Guthrie Evolving therapeutic options for type 2 diabetes mellitus: an overview Postgrad Med 124 6 2012 82 89
2. American Diabetes Association Standards of medical care in diabetes - 2014 Diabetes Care 37 suppl 1 2012 S14 S80
3. National Kidney Foundation KDOQI clinical practice guideline for diabetes and CKD: 2012 update Am J Kidney Dis 60 5 2012 850 886
4. S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 24 2007 2457 2471
5. S. Singh, Y.K. Loke, and C.D. Furberg Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis JAMA 298 10 2007 1189 1195
6. D.J. Drucker, and A.B. Goldfine Cardiovascular safety and diabetes drug development Lancet 377 9770 2011 977 979
7. Food and Drug Administration Center for Drug Evaluation and Research. Guidance for Industry: Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. 2008. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM071627.pdf. Accessed April 9, 2014.
8. A.B. Goldfine Assessing the cardiovascular safety of diabetes therapies N Engl J Med 359 11 2008 1092 1095
9. B.C. Cumbie, and K.L. Hermayer Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications Vasc Health Risk Manag 3 6 2007 823 832
10. J.F. Mann, C. Anderson, P. Gao, and et al. Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial J Hypertens 31 2 2013 414 421
11. H.H. Parving, B.M. Brenner, J.J. McMurray, and et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes N Engl J Med 367 23 2012 2204 2213
12. V. Perkovic, H.L. Heerspink, J. Chalmers, and et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes Kidney Int 83 3 2013 517 523
13. A.H. Barnett, H. Huisman, R. Jones, M. von Eynatten, S. Patel, and H.J. Woerle Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial Lancet 382 9902 2013 1413 1423
14. B. Gallwitz, J. Rosenstock, T. Rauch, and et al. 2-Year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial Lancet 380 9840 2012 475 483
15. J.B. McGill, L. Sloan, J. Newman, and et al. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study Diabetes Care 36 2 2013 237 244
16. O.E. Johansen, D. Neubacher, M. von Eynatten, S. Patel, and H.J. Woerle Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme Cardiovasc Diabetol 11 2012 3
17. U. Graefe-Mody, C. Friedrich, A. Port, and et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(∗) Diabetes Obes Metab 13 10 2011 939 946
18. C. Friedrich, A. Emser, H.J. Woerle, and U. Graefe-Mody Renal impairment has no clinically relevant effect on the long-term exposure of linagliptin in patients with type 2 diabetes Am J Ther 20 6 2013 618 621
19. J. Doupis Linagliptin: from bench to bedside Drug Des Devel Ther. 8 2014 431 446
20. European Medicines Agency. Guideline on Clinical Investigation of Medicinal Products in the Treatment or Prevention of Diabetes Mellitus. 2012. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/06/WC500129256.pdf. Accessed April 9, 2014.
21. A.S. Levey, L.A. Stevens, C.H. Schmid, and et al. A new equation to estimate glomerular filtration rate Ann Intern Med 150 9 2009 604 612
22. G. Orasanu, and J. Plutzky The pathologic continuum of diabetic vascular disease J Am Coll Cardiol 53 5 suppl 2009 S35 S42
23. A.J. Collins, R.N. Foley, C. Herzog, and et al. US Renal Data System 2012 annual data report Am J Kidney Dis 61 1 suppl 1 2013 e1 e480
24. B. Gallwitz Linagliptin - a novel dipeptidyl peptidase inhibitor for type 2 diabetes therapy Clin Med Insights Endocrinol Diabetes 5 2012 1 11
25. J.C. Arjona Ferreira, M. Marre, N. Barzilai, and et al. Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency Diabetes Care 36 5 2013 1067 1073
26. V. Lukashevich, A. Schweizer, Q. Shao, P.H. Groop, and W. Kothny Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial Diabetes Obes Metab 13 10 2011 947 954
27. M. Nowicki, I. Rychlik, H. Haller, and et al. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study Int J Clin Pract 65 12 2011 1230 1239
28. U. Panchapakesan, A. Mather, and C. Pollock Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease Clin Sci (Lond) 124 1 2013 17 26
29. P.H. Groop, M.E. Cooper, V. Perkovic, A. Emser, H.J. Woerle, and M. von Eynatten Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction Diabetes Care 36 11 2013 3460 3468
30. P.W. de Leeuw ACP Journal Club. Aliskiren increased adverse events in patients with diabetes and kidney disease who were receiving ACE inhibitors or ARBs Ann Intern Med 158 6 2013 JC7
31. M.L. Alter, I.M. Ott, K. von Websky, and et al. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy Kidney Blood Press Res 36 1 2012 119 130
32. Y. Ishibashi, T. Matsui, S. Maeda, Y. Higashimoto, and S. Yamagishi Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor Cardiovasc Diabetol 12 2013 125
33. K. Kanasaki, S. Shi, M. Kanasaki, and et al. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen Diabetes 63 6 2014 2120 2131
34. S. Nakashima, T. Matsui, M. Takeuchi, and S.I. Yamagishi Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis Horm Metab Res 46 10 2014 717 721
35. R. Nistala, J. Habibi, A. Aroor, and et al. DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the Zucker obese rat Obesity 22 10 2014 2172 2179
36. B.M. Brenner, M.E. Cooper, D. de Zeeuw, and et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 12 2001 861 869
37. E.J. Lewis, L.G. Hunsicker, W.R. Clarke, and et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 12 2001 851 860